Patents by Inventor Peter Sean Cameron

Peter Sean Cameron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11555181
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: January 17, 2023
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Publication number: 20210102183
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Applicant: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Scott David Gradia, Sanne Eveline Klompe, Samuel Henry Sternberg, Matthew Scott Thompson
  • Publication number: 20210002622
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Application
    Filed: September 21, 2020
    Publication date: January 7, 2021
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10781432
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: March 19, 2020
    Date of Patent: September 22, 2020
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Publication number: 20200277588
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Application
    Filed: March 19, 2020
    Publication date: September 3, 2020
    Applicant: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10597648
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: October 28, 2019
    Date of Patent: March 24, 2020
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Publication number: 20200048622
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 13, 2020
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10457922
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 29, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10329547
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 25, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10227576
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: March 12, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Stemberg
  • Publication number: 20180171360
    Abstract: Methods for use with Type II CRISPR-Cas9 systems for increasing Cas9-mediated genome engineering efficiency are disclosed. The methods can be used to decrease the number of off-target nucleic acid double-stranded breaks and/or to enhance homology-directed repair of a cleaved target nucleic acid.
    Type: Application
    Filed: February 2, 2018
    Publication date: June 21, 2018
    Inventors: Peter Sean Cameron, Rachel E. Haurwitz, Andrew P. May, Christopher H. Nye, Megan van Overbeek
  • Patent number: 9970030
    Abstract: Methods for use with Type II CRISPR-Cas9 systems for increasing Cas9-mediated genome engineering efficiency are disclosed. The methods can be used to decrease the number of off-target nucleic acid double-stranded breaks and/or to enhance homology-directed repair of a cleaved target nucleic acid.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: May 15, 2018
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Rachel E. Haurwitz, Andrew P. May, Christopher H. Nye, Megan van Overbeek
  • Publication number: 20160257973
    Abstract: Methods for use with Type II CRISPR-Cas9 systems for increasing Cas9-mediated genome engineering efficiency are disclosed. The methods can be used to decrease the number of off-target nucleic acid double-stranded breaks and/or to enhance homology-directed repair of a cleaved target nucleic acid.
    Type: Application
    Filed: August 26, 2015
    Publication date: September 8, 2016
    Inventors: Peter Sean Cameron, Rachel E. Haurwitz, Andrew P. May, Christopher H. Nye, Megan van Overbeek